Physician profile
Russell Wayne Rhoades
NPI 1164436507
$4,673.19
in general payments reported to CMS, 2019-2025
39 companies · $1,685 in 2025
The $1,685 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $541 · 2023: $1,124 · 2024: $1,323 · 2025: $1,685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,132.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $869.09 | 2022-2025 | |
| Lilly USA, LLC | $488.46 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $377.71 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $301.16 | 2023-2025 | Shingrix, Arexvy |
| Amgen INC. | $286.91 | 2022-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $283.80 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.59 | 2022-2025 | Jardiance, Tradjenta, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $246.78 | 2022-2025 | |
| Pfizer INC. | $245.14 | 2022-2025 | |
| Astellas Pharma US INC | $143.48 | 2023-2024 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $134.35 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $108.35 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $75.06 | 2024-2025 | |
| Averitas Pharma INC. | $72.38 | 2023-2025 | Qutenza |
| Neurocrine Biosciences, INC. | $68.54 | 2023-2025 | Ingrezza, Ongentys |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $55.32 | 2022-2023 | |
| Edwards Lifesciences Corporation | $54.52 | 2022-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Janssen Pharmaceuticals, INC | $51.78 | 2022-2024 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $43.00 | 2023 | Seglentis, Livalo |
| Baxter Healthcare | $41.47 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Radius Health, INC. | $40.64 | 2023 | Tymlos |
| Sanofi Pasteur INC. | $38.46 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $37.66 | 2024-2025 | Uptravi, Opsumit |
| Sumitomo Pharma America, INC. | $35.54 | 2023-2024 | Gemtesa |
| Merck Sharp & Dohme LLC | $34.06 | 2025 | Capvaxive |
| Idorsia Pharmaceuticals US INC | $32.20 | 2024 | Quviviq |
| Daiichi Sankyo INC. | $29.32 | 2025 | Injectafer |
| Corcept Therapeutics | $25.62 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.25 | 2025 | Caplyta |
| Boston Scientific Corporation | $18.64 | 2023 | Wavewriter Alpha Prime 16 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.58 | 2023 | Xifaxan, Trulance |
| Lundbeck LLC | $17.49 | 2023 | Rexulti |
| Aimmune Therapeutics, INC. | $17.29 | 2024 | |
| Dexcom, INC. | $16.74 | 2024 | Dexcom G6 Transmitter |
| Almatica Pharma LLC | $14.65 | 2023 | Loreev Xr |
| Neurelis, INC. | $14.62 | 2023 | Valtoco |
| Arbor Pharmaceuticals, INC. | $14.43 | 2022 | |
| Grifols USA, LLC | $13.56 | 2024 | Prolastin-C Liquid |
| Lucid Diagnostics INC. | $12.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Rhoades listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.